Business Wire

IL-WEBER

16.5.2024 16:01:31 CEST | Business Wire | Press release

Share
Weber LUMIN Electric Grill Wins Prestigious Red Dot Award for Product Design

Weber LLC, the global leader in outdoor cooking innovation, technology, and products, announced today its LUMIN electric grill received a Red Dot Award in the Red Dot Award: Product Design 2024 competition. The Red Dot Design Award, established in 1955, is one of the world’s largest and most prestigious design competitions, receiving more than 20,000 annual submissions from approximately 60 countries worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516349562/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Weber LUMIN electric grill received a Red Dot Award in the Red Dot Award: Product Design 2024 competition. (Photo: Business Wire)

The Weber LUMIN electric grill, featuring a sleek, space-efficient, contemporary silhouette, received the Red Dot Award for its innovative and high-quality design. It is an ideal grill for outdoor cooks with limited space who desire eco-conscious fuel choices, or who live in a location where other forms of grilling are not permitted.

ABOUT THE LUMIN ELECTRIC GRILL

The LUMIN electric grill, introduced in 2023, is a highly versatile, multifunctional product. Its ultra-modern, space-efficient design makes it ideal for smaller outdoor areas such as balconies and terraces.

To create a “next-level” electric cooking experience, Weber product experts engineered this first-of-its-kind grill to:

  • Reach high heat temperatures of more than 600°F/315°C so that cooks can achieve that mouthwatering, authentically grilled flavor they have come to love with Weber products; owners can reach high heat-searing temperatures within 15 minutes.
  • Infuse vegetables and proteins with rich, smokey tastes through a unique smoke mode.
  • Steam vegetables, braise sausages, and keep cooked food warm via different cook settings and specially designed accessories.
  • Thaw frozen foods directly on the grill while it preheats to save time and simplify mealtime.
  • Make clean-up easy with a front-access grease tray and dishwasher-friendly, porcelain-enamel cast iron cooking grates.

The LUMIN electric grill also features a porcelain-enamel steel lid and cookbox for superior durability and long-term corrosion resistance.

The LUMIN electric grill is available for purchase on weber.com and from retail partners across the Americas and Europe. Outdoor cooks can select from full-size or compact models and a variety of vibrant colors, including Ice Blue, Deep Ocean Blue, Golden Yellow, Seafoam Green, Crimson, and timeless Black. Available models and colors vary by geographic region.

ABOUT RED DOT DESIGN AWARDS

Every year, the renowned Red Dot Award: Product Design honors products that impress with their exceptionally high design quality. The award is based on the decision of the Red Dot jury, which consists of 39 experts from 20 countries on four continents. The experts assess the submissions based on the four basic principles of good design: the quality of function, the quality of seduction, the quality of use and the quality of responsibility.

ABOUT WEBER LLC

Weber LLC, headquartered in Palatine, Ill., is the world’s leading barbecue brand. The Company’s founder George Stephen, Sr., established the outdoor cooking category when he invented the original kettle charcoal grill more than 70 years ago. Weber offers a comprehensive, innovative product portfolio, including charcoal, gas, pellet, electric grills, smokers, griddles and accessories, designed to bring people together to create amazing memories and delicious food. Weber offers its products, services and experiences to a passionate community of millions across 78 countries.

WEBER and LUMIN are registered U.S. and EU trademarks owned by Weber-Stephen Products LLC. WEBER and LUMIN are also the subject of registrations or pending applications in other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240516349562/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release

Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye